Ophthalmic pharmaceutical compositions containing dorzolamide, methods for their preparation and use.

Abstract

The present invention provides ophthalmic pharmaceutical compositions for the treatment of IOP that are prepared by a preparation method that allows the treatment of known active ingredients and their salts in such a way that a sufficiently stable base-type form of the active ingredients is produced and then introduced into different carrier matrices that produce a final product that is stable at critical pH values ​​and allows the use of API concentrations never before explored with adequate bioavailability and avoiding all those side effects collectively known as "burning sensations".